Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis?
Takayasu arteritis (TAK) is an idiopathic systemic disease characterized by granulomatous inflammation of the aorta and its branches. TAK can cause multiple vascular injuries throughout the body, mainly arterial stenosis and aneurysms. In severe cases, it can even lead to fatal hemorrhage, infarctio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1593770/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849430998574432256 |
|---|---|
| author | Congqi Hu Lingjie Liu Hui Xiao Hongjun Zhao Guangxing Chen Yanli Xie |
| author_facet | Congqi Hu Lingjie Liu Hui Xiao Hongjun Zhao Guangxing Chen Yanli Xie |
| author_sort | Congqi Hu |
| collection | DOAJ |
| description | Takayasu arteritis (TAK) is an idiopathic systemic disease characterized by granulomatous inflammation of the aorta and its branches. TAK can cause multiple vascular injuries throughout the body, mainly arterial stenosis and aneurysms. In severe cases, it can even lead to fatal hemorrhage, infarction and other serious complications, posing a serious threat to the patient’s life and health. Few studies have shown that drug treatment can improve or reverse its vascular stenosis. This study describes a 19-year-old woman diagnosed with TAK who had multiple vascular stenosis at the time of the disease. In an early and timely manner as well as up to seven years after a full course of tolizumab, her vascular wall thickening improved and previously stenotic vessels were recanalized. We believe that early use of tocilizumab in patients with TAK can improve vascular lesions. To our knowledge, this study is the first case to find complete recanalization of stenotic vessels after the use of tocilizumab, and the pre- and post-test and examination data are complete. In addition, we summarized the cases of improvement of vascular lesions after tocilizumab treatment of TAK, and preliminarily compared the efficacy and safety of tocilizumab and TNFi in TAK. We speculate that early and adequate use of tocilizumab could reverse early inflammatory vessel wall thickening and stenosis, and we found, through further literature review, that its efficacy was comparable to that of TNF inhibitors |
| format | Article |
| id | doaj-art-dd27f40e0ad74ea18df7659a18b34dc8 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-dd27f40e0ad74ea18df7659a18b34dc82025-08-20T03:27:47ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15937701593770Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis?Congqi Hu0Lingjie Liu1Hui Xiao2Hongjun Zhao3Guangxing Chen4Yanli Xie5Department of Rheumatology Nephrology, Baiyun Hospital The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaFirst Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaDepartment of Rheumatology Nephrology, Suining County People’s Hospital, Shaoyang, Hunan, ChinaDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Rheumatology Nephrology, Baiyun Hospital The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaTakayasu arteritis (TAK) is an idiopathic systemic disease characterized by granulomatous inflammation of the aorta and its branches. TAK can cause multiple vascular injuries throughout the body, mainly arterial stenosis and aneurysms. In severe cases, it can even lead to fatal hemorrhage, infarction and other serious complications, posing a serious threat to the patient’s life and health. Few studies have shown that drug treatment can improve or reverse its vascular stenosis. This study describes a 19-year-old woman diagnosed with TAK who had multiple vascular stenosis at the time of the disease. In an early and timely manner as well as up to seven years after a full course of tolizumab, her vascular wall thickening improved and previously stenotic vessels were recanalized. We believe that early use of tocilizumab in patients with TAK can improve vascular lesions. To our knowledge, this study is the first case to find complete recanalization of stenotic vessels after the use of tocilizumab, and the pre- and post-test and examination data are complete. In addition, we summarized the cases of improvement of vascular lesions after tocilizumab treatment of TAK, and preliminarily compared the efficacy and safety of tocilizumab and TNFi in TAK. We speculate that early and adequate use of tocilizumab could reverse early inflammatory vessel wall thickening and stenosis, and we found, through further literature review, that its efficacy was comparable to that of TNF inhibitorshttps://www.frontiersin.org/articles/10.3389/fimmu.2025.1593770/fullTakayasu arteritistocilizumabTNFivascular stenosis and recanalizationcure |
| spellingShingle | Congqi Hu Lingjie Liu Hui Xiao Hongjun Zhao Guangxing Chen Yanli Xie Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis? Frontiers in Immunology Takayasu arteritis tocilizumab TNFi vascular stenosis and recanalization cure |
| title | Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis? |
| title_full | Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis? |
| title_fullStr | Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis? |
| title_full_unstemmed | Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis? |
| title_short | Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis? |
| title_sort | case report can early full course tocilizumab therapy reverse vascular stenosis in takayasu arteritis |
| topic | Takayasu arteritis tocilizumab TNFi vascular stenosis and recanalization cure |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1593770/full |
| work_keys_str_mv | AT congqihu casereportcanearlyfullcoursetocilizumabtherapyreversevascularstenosisintakayasuarteritis AT lingjieliu casereportcanearlyfullcoursetocilizumabtherapyreversevascularstenosisintakayasuarteritis AT huixiao casereportcanearlyfullcoursetocilizumabtherapyreversevascularstenosisintakayasuarteritis AT hongjunzhao casereportcanearlyfullcoursetocilizumabtherapyreversevascularstenosisintakayasuarteritis AT guangxingchen casereportcanearlyfullcoursetocilizumabtherapyreversevascularstenosisintakayasuarteritis AT yanlixie casereportcanearlyfullcoursetocilizumabtherapyreversevascularstenosisintakayasuarteritis |